First signs if a COVID-19 vaccine works possible in autumn - GAVI


  • World
  • Sunday, 24 May 2020

FILE PHOTO: A 3D-printed coronavirus model is seen in front of the words coronavirus disease (COVID-19) on display in this illustration taken March 25, 2020. REUTERS/Dado Ruvic/Illustration

ZURICH (Reuters) - First indications of the effectiveness of a potential vaccine against coronavirus may be available in the autumn, the head of the GAVI vaccine alliance told a Swiss newspaper, forecasting a long road from there to broad availability.

"Unfortunately, we really do not know which vaccine will work and whether there will be one at all. If we're lucky, we'll receive indications in autumn as to (a potential vaccine's) effectiveness," GAVI head Seth Berkley told NZZ am Sonntag in an interview published on Sunday.

"But there will still be a long way to go from there until an approved active substance becomes available in large quantities for the global population."

Calling for globally coordinated efforts both to produce and share an eventual vaccine, Berkley said international agreement was needed to build up manufacturing capacity to rapidly produce a vaccine once one is found.

"(Countries) should work together in order to share in each other's vaccines in case one's own are not good," he said, adding it was possible some vaccines would work better for younger people and others for older age groups.

He urged the Wealth Health Organization to issue clear guidelines on a vaccine's use and distribution to prevent a vaccine first being made available to the rich at the expense of the people most in need.

Should an effective vaccine become available in an initially limited supply, it should first be used to immunise health personnel, he said.

(Reporting by Brenna Hughes Neghaiwi; Editing by Mark Potter)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

97% readers found this article insightful

Across the site